Clinical Evaluation: Combined Visual Inspection and Pap for Cervical Cancer Prevention

Similar documents
The experience with. carehpvin El Salvador

New guidelines for cervical cancer prevention and control

New Guidelines OMS and ASCO. Jose Jeronimo M.D. Associate Director Reproductive Health PATH Seattle, WA, USA

Case Based Problems. Recommended Guidelines. Workshop: Case Management of Abnormal Pap Smears and Colposcopies. Disclosure

HIV Status Effect on Cervical Cancer Screening in Three Countries: Paper Presentation

Cervical Cancer Prevention

WOMEN S INTERAGENCY HIV STUDY LABORATORY - PELVIC EXAM STUDIES TREATMENT FORM FORM L16

Preventing Cervical Cancer 2018 WHAT THIS WILL MEAN FOR PRIMARY CARE

An Update on Cervical Cancer Screening Recommendations and on the DOH BCC Program

Cervical Cancer Research in South Africa

State Breast and Cervical Cancer Early Detection Program WEAVING Survey

Goals. In the News. Primary HPV Screening 3/9/2015. Your PAP and HPV Update Primary HPV Testing- Screening Intervals- HPV Vaccine Updates-

NATIONAL CERVICAL CANCER SCREENING PROGRAMME Monitor 2017

CARIBBEAN CANCER NETWORK THE BELIZE CANCER SOCIETY S PERSPECTIVE CERVICAL CANCER ADVOCACY WORKSHOP ST. MAARTEN MARCH 22, 2013.

Screening for Chronic Disease. Prof. A. Miller

I have no financial interests in any product I will discuss today.

SCALING UP VIA AND CRYOTHERAPY: Challenges, Opportunities and Essential Program Practices

Cervical Cancer Control in Latin America and the Caribbean ROUNDTABLE POLICY BRIEF. Dr Rolando Camacho Rodríguez

Cervical Cancer Screening

Dr. Nathalie Broutet Reproductive Health and Research, WHO

A workshop on screening for cervical

Cancer 376 Causes of cancer 376 Cancer can be cured if found and treated early 376

BCCCNP NEW PROGRAM FORMS WEBINAR. January 8, 2019 E.J. Siegl, Program Director Breast and Cervical Cancer Control Navigation Program

Breast and Cervical Cancers in Barbados A Situational Analysis HEATHER ARMSTRONG MEDICAL OFFICER OF HEALTH, MINISTRY OF HEALTH, BARBADOS

Cancer 376 Causes of cancer 376 Cancer can be cured if found and treated early 376

PAHO WORKSHOP ON CERVICAL CANCER PREVENTION STRATEGIES USING VIA SCREENING AND CRYOTHERAPY TREATMENT

WHO Africa Region Cervical Cancer Control Policies and Strategies

Seeing is Believing: VIA and the Single-Visit- Approach to Cervical Cancer Prevention

SESSION J4. What's Next? Managing Abnormal PAPs in 2014

TREATMENT OF VIA/VILI POSITIVE CASES

Focus on Cervical Cancer: Key Messages. Cancer System Quality Index 2016

Alabama Department of Public Health County Health Department Protocol

FY 2015 BCCCP Procedure Code Reference Chart

Combatting Cervical Cancer in Low-Resource Settings. Strategic Partnership January 28, 2019

Public Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE

RESULTS OF BREAST AND CERVICAL CANCERS SCREENING IN HAIPHONG WITHIN 5 YEARS FROM 2011 TO Hoa Nguyen Lam, Huyen Suong Ho Thi et al.

Manitoba Cervical Cancer Screening Program. Operations & Statistical Report and 2006

Preventing Cervical Cancer Through Effective Data Use: Practical Tools

Cervical Cancer Screening. David Quinlan December 2013

Infection as a non-communicable disease: A cervical cancer prevention primer

HPV & CERVICAL CANCER POLICY & LEGISLATIVE TOOLKIT, 3 RD EDITION

Partha Basu M.D. Screening Group/ Early Detection & Prevention Section

What Causes Cervical Cancer? Symptoms of Cervical Cancer

Your Colposcopy Visit

Clinical outcomes after conservative management of CIN1/2, CIN2, and CIN2/3 in women ages years

Clinical Guidance: Recommended Best Practices for Delivery of Colposcopy Services in Ontario Best Practice Pathway Summary

Cuid d Fheidhmeannacht na Seirbhíse Sláinte. Part of the Health Service Executive. CS/PR/PM-20 Rev 2 ISBN Programme Report 2014/2015

Putting evidence into practice: Dissemination and implementation of an evidencebased cervical cancer prevention project in Ethiopia

REVIEW OF SCREENING RECOMMENDATIONS FROM AROUND THE WORLD: Perspective of the IFCPC

What is a Pap Smear and What do the results mean? Maria E Daheri RN Cervical Nurse Case Harris Health System

Alabama Breast and Cervical Cancer Early Detection Program (ABCCEDP) County Health Department Protocol

How do we compare? IP724/BMTRY Introduction to Global and Public Health. Feb 21, 2012 Basic Science Rm Sharon Bond, PhD, CNM

Cytology Update M Laing QEUH

Screening for Cervical Cancer: Demystifying the Guidelines DR. NEERJA SHARMA

Camelia Davtyan, MD, FACP Clinical Professor of Medicine Director of Women s Health UCLA Comprehensive Health Program

Put i2itracks on the Fast Track. Nancy Thompson

Protect yourself: Get screened for breast cancer

07 August Dear Colleague,

Evidence-Based, Alternative Cervical Cancer Screening Approaches in Low-Resource Settings

Understand Your Results

International Federation of Gynecology and Obstetrics

Collabora'on to Prevent and Control Cervical Cancer in La'n America and the Caribbean

Healthy Caribbean 2012 Rallying for Action on NCDs

Screening Mammograms: Questions and Answers

BCCCNP Service CPT Code FY 2019 Rate Oct 1, 2018 Dec 31, 2018

BCCCNP Service CPT Code FY19 Rate. $ $97.98 $ Diagnostic Breast Tomosynthesis (Bilateral) 3D Mammogram a. Global

I have no financial interests to disclose.

$ $97.98 $ a. Diagnostic Breast Tomosynthesis (Bilateral) 3D Mammogram a. Global. $47.61 b. Technical/Facility Only

2017 NBCCEDP Allowable Procedures and Relevant CPT Codes

Early Detection Works Breast and Cervical Cancer Detection Program in Kansas. Welcome!

The Pap Smear Test. The Lebanese Society of Obstetrics and Gynecology. Women s health promotion series

ASCCP Guideline Changes and Management of the Abnormal Pap Test Accurately Targeting Intervention

Human Papillomavirus. Kathryn Thiessen, ARNP, ACRN The Kansas AIDS Education and Training Center The University of Kansas School of Medicine Wichita

FY 2017 BCCCNP Unit Cost Reimbursement Rate Schedule

Cervical Screening for Dysplasia and Cancer in Patients with HIV

Samuel B. Wolf, D.O., F.A.C.O.G. Emerald Coast Obstetrics and Gynecology Panama City Florida

Cervical Cancer 4/27/2016

A REVIEW OF NATIONAL CANCER CONTROL PLAN.? PROPOSALS FOR

Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???

Challenges and successes with cervical cancer early detection and treatment in Kenya

HPV, Cervical Dysplasia and Cancer

QA and Quality Indicators for Cervical Cancer Screening Programs. Guglielmo Ronco MD Senior Epidemiologist CPO Piemonte Turin, Italy

Management Algorithms for Abnormal Cervical Cytology and Colposcopy

Improving Women s Health in South Carolina Best Chance Network and WISEWOMAN. Dr. Trenessa K. Jones Best Chance Network Program Director

Becoming a colposcopist: Colposcope case studies

Why HPV Screening Which Problems What Methods

WHO Global Strategies in Cervical Cancer Prevention and Control

Lauren O Sullivan, D.O. February 19, 2015

Dysplasia: layer of the cervical CIN. Intraepithelial Neoplasia. p16 immunostaining. 1, Cervical. Higher-risk, requires CIN.

CERVICAL CANCER FACTSHEET. What is cervical cancer?

Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines

Pap Test. F r e q u e n t l y A s k e d Q u e s t i o n s

The new Cervical Screening Test for Australian women: Louise Farrell

Objectives. Background. Background. Background. Background 9/26/16. Update on Cervical and HPV Screening Guidelines: To pap or not to pap?

HIV and AIDS Related Cancers DR GORDON AMBAYO UHS

Cancer Screening Program in GEORGIA

Details of HPV-based Cervical Cancer Screening in Turkey

Re: Microbiology Medical Devices Panel on Cobas HPV Test Premarket Approval Application

Annual Progress Report to IFPMA

National Women's Hospital Annual Clinical Report. Gynaecological Oncology and Colposcopy

Transcription:

Clinical Evaluation: Combined Visual Inspection and Pap for Cervical Cancer Prevention Clínica Fara, Matagalpa, Nicaragua Susan Howe, MPH Dra. Oneyda Chavarria D, MD Dr. Kay Edwards, Ph.D, Haverford College

Why Cervical Cancer & Why Nicaragua & Why Visual Inspection

Incidence of cervical cancer from estimates for 2008

NICARAGUA Cervical Cancer in Nicaragua 2008 Rate age standardized Ranking in South & Central America & the Caribbean Ranking in the World Incidence 39.9 # 3 # 15 Mortality 20.9 # 1 # 27 Comparison of cancer rates -- data from 184 countries Based on crude rates standardized per 100,000. Cumulative Risk [0-74] percent GLOBOCAN 2008, IARC -22.12.2011 World Health Organization / International Agency for Cancer Research

WHO Summary Report, Nicaragua, 2010

Cervical cancer is one of the prinicipal causes of death for women in Nicaragua over 30 Although maternal mortality is of concern in Nicaragua in 2008 there were 2 1/2 times more cervical cancer deaths than maternal deaths Maternal Deaths due to deaths cervical cancer 85 216 487 invasive cases treated in the National Radiation Center

Despite having a Pap program in place for over 30 years Low coverage Older women (Age >30) are missed Focus on younger women coming for pre-natal control & family planning Need for more health promotion/outreach Poor sensitivity Little quality control Results don t get to patients Poor follow-up

What is Visual Inspection with Acetic Acid (VIAA)? Conduct pelvic exam with a speculum Apply vinegar to the cervix (white vinegar -- 5%, no salt or spices) Wait 2 minutes Look for white spots or changes

Categories of results with VIAA Suspicious for Cancer Negative Positive

CLÍNICA FARA Private clinic for low income patients, subsidized by a local family foundation, the Fara Foundation Referral center that collaborates with Ministry of Health, NGOs, other community clinics & organizations http://www.farafoundation.org/clinica-fara

CLÍNICA FARA Provides services hard to find in public health system Cancer prevention services Varicose vein treatment Dental services Education and counseling Other general medical services

Focus on women s cancer Clinic is developing a program of early cancer detection and prevention services in the north of Nicaragua Cervical Cancer Early diagnosis and treatment (VIAA, Pap, Colpo, Biopsy, Cryotherapy & LEEP) Diagnostic services needed prior to cancer treatment in Capital, in Managua (Cistoscopy) Breast Cancer Early diagnosis (ultrasound and fine needle aspiration)

Why evaluate VIAA at Clínica Fara? Clínic Fara: Uses a clear protocol for screening, diagnostic work-up and treatment Keeps good patient records Has reliable patient follow-up Maintains an electronic database available for analysis of all procedures & results Has an epidemiologist on-site Objective of evaluation Monitor the Clinic s protocol for ongoing program improvement Share the clinic s experience to help implement and evaluate VIAA in Nicaragua

Clínica Fara VIAA & Pap protocol

Cervical cancer prevention program at Clínica Fara 2011-2013 379 (13%) patients were referred to the clinic for diagnostic work-up of abnormalities detected by other providers 2438 (87%) patients were screened for cervical cancer using 3 different screening protocols 1. VIAA + PAP: 817 2. Pap Only: 1,462 3. VIAA Only: 159 Total 2,438 The evaluation that follows is focused on the group that received both VIAA & Pap

Results of screening with VIAA & Pap VIAA PAP No No Colpo Colpo Performed Biopsy Bx. Normal Lowgrade (CIN 1/ HPV) High-grade (CIN2/CIN3/ Ca in Situinvasive) Pos Pos 87 3 84 75 1 65 9 Pos Neg 69 4 65 53 3 43 7 Neg Pos 96 42 54 24 5 16 3 Neg Neg 565 557 8 6 5 1 Total 817 211 158 14 125 19 VIAA positive: 156 ( 19%) 108 Low-grade lesions ( 70%) 16 High-grade lesions ( 10%) 84 % of High-grade lesions were detected by VIAA Pap positive: 183 ( 22%) 81 Low-grade lesions ( 44%) 12 High-grade lesions ( 7%) 64 % of High-grade lesions were detected by Pap ( 32% by High-grade Pap) ( 32% by Low-grade Pap)

How were high-grade (CIN2+) lesions detected? VIAA Pap Biopsy High-grade (CIN2+) VIAA Pos 84% VIAA Pos Pap Pos 9 VIAA Pos Pap Neg 7 VIAA Neg 16% VIAA Neg Pap Pos 3 VIAA Neg Pap Neg 0 Pap Pos 64% Total 19 Pap Neg 36%

High-grade (CIN 2+) lesions by grade of Pap VIAA Pap Biopsy High-grade Lesion (CIN2+) % of Total (CIN2+) VIAA Pos Pap HG 4 21% Pap LG 5 26% Pap Neg 7 36% VIAA Neg Pap HG 2 11% Pap LG 1 5% Pap Neg 0% Total 19 VIAA Pos 84% Pap HG 32% Pap LG 32% Pap Neg 36% VIAA Neg 16%

High-grade lesions (CIN 2+) by results of screen Pap HG VIAA Neg 11% Pap Neg VIAA Pos 36% Pap LG VIAA Neg 5% Pap HG VIAA Pos 21% Pap LG VIAA Pos 26% VIAA+ Pap HG VIAA+ Pap LG VIAA+ Pap Neg VIAA- Pap HG VIAA- Pap LG VIAA- Pap Neg

Rate of detection of high-grade lesions Detection rate depends primarily on two major factors 1. Sensitivity of the screening test 2. Proportion of high-risk women reached High-risk = More than 30 years old & More than 3 years from last screen

Rate of detection of high-grade lesions (CIN2+) at Clinica Fara VIAA & Pap (N=817) Rate of detection of high-grade lesions 2.3% % of high-risk* women 44% * High-risk = >30 years old & >3 years since last screen

Comparison with other programs in Nicaragua -- Rivas 2000-2003

Comparison with other programs in Nicaragua Clínca Fara Rivas / MINSA # Examined (817) (1076) Rate of Detectión 2.3% 4.7% % High Risk 44% 75% Detection by VIAA 2.0% 4.2% Detection by Pap 1.5% 2.1% High-grade Pap 0.7% Low-grade Pap 0.7%

Conclusions: What have we learned? Clinica Fara should: Continue combined VIAA and Pap protocol Work up all VIAA positives and high-grade Pap results Follow up (6-month rescreening) low-grade Pap results Expand the VIAA and Pap protocol Cover all patients receiving cervical cancer screening Train other clinic providers in VIAA Share these findings with: Other organizations (NGOs) working in cervical cancer prevention in Nicaragua, and Ministry of Health, as it evaluates its own VIAA screening protocols

Diagnostic work-up versus Screen and Treat What is Screen & Treat? Treat VIAA positives with cryotherapy at the same first screening visit (if adequate for cryotherapy) Advantages: Immediate counseling & treatment while woman is at health center Reduced loss to follow-up Challenges: Post treatment follow-up necessary due to (10-15% failure rate on high-grade lesions) Overtreatment of low-grades (70%) and normals (20%)

WHO recomends Screen and Treat for low-resources settings Use a strategy of screen with an HPV test and treat, over a strategy of screen with VIA and treat. In resource constrained settings, where screening with an HPV test is not feasible, the panel suggests a strategy of screen with VIA and treat. Use a strategy of screen with VIA and treat, over a strategy of screen with cytology followed by colposcopy (with or without biopsy) and treat. The recommendation for VIA over cytology followed by colposcopy can be applied in countries that are currently considering either programme or countries that currently have both programmes available.

Advantages of VIAA More sensitive Immediate results No laboratory required Can treat at the same visit Sceen and Treat Disadvantages of VIAA High rate of positives Some overtreatment if Screen and Treat used More patients referred if referral used Advantages of Pap High-grade is more specific (fewer referrals) Disadvantages of Pap Not very sensitive (<40%) Problems with results Lengthy delay Patients don t receive results Barriers to follow-up Find the patient, appointment, transport & lodging

Suggestions to support & expand VIAA screening Train more providers in VIAA & cryotherapy Equip more health centers with cryotherapy Develop system to maintain gas supplies for cryotherapy equipment Develop maintenance system for cryotherapy equipment Strengthen outreach to high-risk women through community health networks

Natural history / life cycle of HPV infection

Decline of cervical cancer mortality rates in United States